Proving a revenue dip was timing, not decline

The situation

Niran's message arrived on a Thursday afternoon, three weeks from the target signing date: his firm was no longer comfortable at the agreed price, and unless the number came down by roughly eight percent, they would need to revisit the entire structure. The stated reason was one quarter of softer revenue that had shown up in the data room two weeks earlier, at the exact moment a competing bidder had already dropped out and Giulia's side had stopped shopping the deal to anyone else.

The business at the centre of it was a specialty pharmacy distribution company that Giulia had built from a single compounding pharmacy into a regional operation supplying long-term care facilities and managing complex, multi-drug medication programs for patients who could not manage them alone. A private equity sponsor had bought a majority stake five years earlier, with Giulia staying on as chief executive and a minority holder alongside the fund. Anong, a commercial pilot who had been an early personal investor in the original pharmacy before the sponsor ever became involved, held a smaller stake and a board seat, and had watched the business grow from something run out of a single storefront into a regional supplier with dozens of institutional contracts.

The sponsor was now running a structured sale process to exit its position after five years, in a sale valued at roughly forty million dollars, on a timeline set well before anyone knew a quarter would come in soft. Niran represented the private equity firm that had emerged as the lead bidder in what the industry calls a secondary buyout: one financial sponsor selling a portfolio company to another financial sponsor, rather than to a strategic industry acquirer or back to public markets through an offering. Secondary buyouts move faster than most sales because both sides know the playbook cold, but that speed creates a particular vulnerability of its own.

The buying sponsor's own investment committee has to approve a price based on a snapshot of performance taken at a specific moment, and any wobble in the numbers between signing a letter of intent and finalizing the purchase agreement becomes ammunition for a committee looking for leverage, whether or not the wobble reflects anything real happening inside the business. The soft quarter here was real. Revenue had come in roughly six percent below the prior quarter, and the buyer's diligence team had flagged it as a possible sign that the long-term care contracts underpinning the whole valuation were softer than represented. Giulia believed the dip was explainable. Believing it and proving it to a skeptical buyer's investment committee under a real deadline were two very different problems, and the purchase agreement did not leave much room left for solving the second one slowly.

The risk we had to size

The purchase agreement Giulia's side had already signed a letter of intent around included representations about the business operating in the ordinary course and about no material adverse change occurring before closing. Niran's firm was not formally invoking a material adverse change clause, which is a high legal bar and genuinely hard to satisfy on the strength of a single soft quarter, but they did not need to invoke anything formal. They only needed enough doubt to justify a price reduction their own investment committee could accept internally without a fight, and a six percent revenue dip discovered late in diligence was exactly the kind of ambiguous fact that manufactures doubt on demand.

The risk we had to size was not legal in the narrow sense of a clause being breached. Nothing in the letter of intent obligated either side to close at the original price, and a soft quarter genuinely could, in a different business, reflect a company under real strain. The practical risk was that Giulia's team would respond to the pressure with explanations rather than evidence, that the sponsor, five years into an investment and eager to exit on schedule, would get anxious about losing months of process if the deal collapsed and started over, and that a real eight percent price cut would get accepted as the path of least resistance even though nothing about the underlying business had actually changed in any way that mattered.

We also had to size how much time was genuinely available to respond properly rather than react. Niran's firm had not withdrawn from the deal, which told us their investment committee wanted this transaction to happen and was looking for cover to proceed at the original number, not an actual excuse to walk away from months of their own diligence work. That reading mattered a great deal, because it meant the right response was not to threaten to shop the deal elsewhere, which would have cost more time than anyone in the process actually had left, but to give the buyer's own committee something concrete enough to approve without the discount they had opened with.

The explanation Giulia offered informally, that the dip reflected the timing of a large institutional contract's renewal cycle rather than any real loss of business, was plausible but entirely unproven on the record. Plausible explanations offered under pressure by the party who directly benefits from them do not move a skeptical buyer's investment committee, no matter how sincerely they are meant. Something independent of Giulia's own account was needed to close the gap, and critically, it needed to already exist somewhere in the business rather than be built specifically for the occasion, which a buyer's diligence team would treat as suspect on its face.

What we did

1. Reviewed the letter of intent and draft purchase agreement line by line to confirm neither side was contractually bound to close at the original price, and equally that nothing in the drafting entitled the buyer to a unilateral repricing outside a formal, mutual renegotiation. Establishing this clarified that the dispute was purely commercial pressure, not a breach either side could point to, which shaped exactly how firmly we could push back on the buyer's proposed timeline without exposing the client to a real legal risk.
2. Pulled the raw dispensing and fulfillment logs directly from the pharmacy's own operational software, rather than relying on the monthly revenue summaries the diligence team had already been given and reviewed. Summarized financials show that a dip happened; they rarely show why it happened at the level of an individual contract. The underlying transaction-level data was an ordinary operational report nobody on either side of the table had thought to request specifically during the original diligence build-out.
3. Mapped the dip against the institutional contract renewal calendar using that raw transaction data, and found that one long-term care facility contract, representing most of the shortfall on its own, had simply been re-ordered on a delayed cycle that particular quarter rather than genuinely reduced in volume. The same facility's subsequent order, placed only weeks after the quarter closed, showed volume already back at the prior run rate, which undercut the decline theory directly.
4. Assembled the data into a short, factual reconciliation document rather than a persuasive narrative memo, presenting order-level volume by contract and by month so the pattern was visible without interpretation. A buyer's investment committee trusts a spreadsheet they can independently check against source data far more than they trust an explanation coming from the seller's own counsel, however accurate that explanation actually is.
5. Delivered the reconciliation directly to Niran's diligence team, with an open offer to let their own financial advisors verify every line against the pharmacy's live system rather than take the reconciliation on faith. That offer signalled a level of confidence the sponsor's side had not expected, and it removed the natural suspicion that the explanation had been constructed hastily after the fact to save the deal.
6. Held firm on the closing timeline while the buyer's team carried out its own verification, declining to grant an open-ended extension that would have let the pressure campaign continue indefinitely in the background, and instead offering a short, clearly fixed window for their diligence team to confirm the reconciliation and report back to their committee. An open-ended timeline would have cost Giulia's side its own leverage, signalling doubt in the reconciliation and giving the buyer room to keep shopping for a different reason to renegotiate.
7. Prepared Giulia and the sponsor for the possibility that the price reduction request would persist regardless of how strong the evidence turned out to be, including a fallback position built around a smaller, temporary adjustment mechanism tied to the following quarter's actual results, so the negotiation had a workable landing spot even if the data alone did not fully settle the buyer's committee.

The outcome

Niran's diligence team verified the order-level data against the pharmacy's own system within the window given and reported back to their investment committee that the shortfall was attributable to contract timing rather than genuine customer attrition. The price reduction request was withdrawn in full within days of that verification. The deal closed at the originally agreed valuation, with no adjustment mechanism ultimately needed and no delay to the signing date beyond the handful of days spent on verification itself.

The strongest evidence in the entire episode was not a legal argument, a negotiated concession, or anything drafted for the purpose of the sale. It was ordinary transaction-level data the pharmacy's own dispensing system had been recording automatically the whole time, for operational reasons that had nothing to do with a future sale to anyone. Nobody had thought to pull it during the original due diligence build-out because the summarized monthly revenue figures the process normally relies on had looked complete enough on their own, right up until they stopped telling the full story.

Giulia's minority stake and Anong's smaller holding both realized the full value the original sale process had established months earlier, without either being forced to accept a late discount born of pressure and timing rather than any fact about the business itself. The sponsor exited on the original schedule it had planned around, and Niran's firm completed its acquisition with a diligence file it could defend confidently to its own investors, having verified the explanation independently rather than simply taking the seller's word for what the numbers meant.

What made the difference was not a clever legal manoeuvre so much as discipline: refusing to let a genuine ambiguity in the numbers get resolved by whoever pushed hardest, and instead finding the source data that resolved it on its own terms before the deadline forced a worse compromise.

What you can learn from this